Literature DB >> 16297654

Cross-talk between IGF-I and TGF-beta signaling pathways.

David Danielpour1, Kyung Song.   

Abstract

Insulin-like growth factor-I (IGF-I) has gained broad recognition as an important survival factor for epithelial cells in numerous tissues. The IGF-I receptor signaling pathway is deregulated in the majority of carcinomas, and such deregulation has also been reported to be tightly associated with enhanced tumor progression and metastasis. One of the key proteins that transduces IGF-I signals and is phospho-activated downstream of the IGF-I receptor, is the non-receptor serine/threonine kinase proto-oncogene protein kinase B (PKB, also known as Akt). This kinase serves as a major molecular node to control the function of many cell survival and death proteins through phosphorylation-mediated protein modification. The end result of the activation of Akt is enhanced cell survival and proliferation, pre-requisites for malignant transformation. Recent studies show that IGF-I signals cross-talk at multiple levels with various components of the TGF-beta signaling pathway, which depending on context may function either as tumor suppressor or as tumor promoter. Thus, a better understanding of how the IGF-I and TGF-beta signaling pathways are mutually interconnected is likely to unveil novel targets for the therapeutic intervention of many cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16297654     DOI: 10.1016/j.cytogfr.2005.09.007

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  37 in total

1.  The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor.

Authors:  Cecilia A Fernandez; Roopali Roy; Sunyoung Lee; Jiang Yang; Dipak Panigrahy; Krystyn J Van Vliet; Marsha A Moses
Journal:  J Biol Chem       Date:  2010-10-12       Impact factor: 5.157

2.  Autophagy genes unc-51 and bec-1 are required for normal cell size in Caenorhabditis elegans.

Authors:  István Aladzsity; Márton L Tóth; Tímea Sigmond; Emese Szabó; Bertalan Bicsák; János Barna; Agnes Regos; László Orosz; Attila L Kovács; Tibor Vellai
Journal:  Genetics       Date:  2007-09       Impact factor: 4.562

3.  Phosphatase specificity and pathway insulation in signaling networks.

Authors:  Michael A Rowland; Brian Harrison; Eric J Deeds
Journal:  Biophys J       Date:  2015-02-17       Impact factor: 4.033

4.  Crosstalk and competition in signaling networks.

Authors:  Michael A Rowland; Walter Fontana; Eric J Deeds
Journal:  Biophys J       Date:  2012-12-05       Impact factor: 4.033

5.  Regulating the availability of transforming growth factor ß1 in B104 neuroblastoma cells.

Authors:  Amanda L Lindke; Frank A Middleton; Michael W Miller
Journal:  Exp Neurol       Date:  2010-06-12       Impact factor: 5.330

6.  Distinct signalling properties of insulin receptor substrate (IRS)-1 and IRS-2 in mediating insulin/IGF-1 action.

Authors:  Atefeh Rabiee; Marcus Krüger; Jacob Ardenkjær-Larsen; C Ronald Kahn; Brice Emanuelli
Journal:  Cell Signal       Date:  2018-03-14       Impact factor: 4.315

Review 7.  Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies.

Authors:  Jorge A Garcia; David Danielpour
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

8.  Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II.

Authors:  Kyung Song; Hui Wang; Tracy L Krebs; Seong-Jin Kim; David Danielpour
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

Review 9.  Platelet-rich therapies in the treatment of orthopaedic sport injuries.

Authors:  Mikel Sánchez; Eduardo Anitua; Gorka Orive; Iñigo Mujika; Isabel Andia
Journal:  Sports Med       Date:  2009       Impact factor: 11.136

Review 10.  TGFbeta as a potential mediator of progesterone action in the mammary gland of pregnancy.

Authors:  Jenifer Monks
Journal:  J Mammary Gland Biol Neoplasia       Date:  2007-11-20       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.